You can also read the IBTA e-News April 2020 edition in full online here.
Some of the highlights from this month's round-up:
- A special focus on COVID-19 and how its effects on the global brain tumour community, including announcing the launch of the our COVID-19 patient and caregiver survey.
- Details on how to view the “COVID-19 and the brain tumour community” webinar, held on April 22, 2020 in collaboration with the Society for Neuro-Oncology (SNO).
- In the journal Cancer Cell, an international team of researchers has documented the genetic alterations in paediatric low-grade glioma (pLGG) that correspond with better or worse outcomes.
- A large-scale international study, published in Cancer Discovery has found that high grade gliomas in infancy (the first 12 months of life) have a different genetic profile, compared to gliomas in older children, potentially explaining why these early tumours tend to be less aggressive.
- A lab-based study published in Science Translational Medicine has found that niacin (also known as vitamin B3) stimulates immune cells to attack and destroy glioblastoma cells more effectively.
- A novel drug, called 1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine (NSPP), was able to prevent cognitive decline in mice treated with radiation therapy for brain tumours, without dampening the effect of the therapy, according to a paper published in the journal Neuro-Oncology.
- Denovo Biopharma has announced that it is acquiring the entirety of Tocagen's retroviral replicating vector platform (including Toca 511 & Toca FC, which has been renamed DB107).
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.